MAXITROL SUSPENSION

Country: Malaysia

Language: English

Source: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Buy It Now

Active ingredient:

NEOMYCIN SULPHATE; DEXAMETHASONE; POLYMYXIN B SULPHATE

Available from:

NOVARTIS CORPORATION (MALAYSIA) SDN. BHD.

INN (International Name):

NEOMYCIN SULPHATE; DEXAMETHASONE; POLYMYXIN B SULPHATE

Units in package:

5ml mL

Manufactured by:

S.A. ALCON-COUVREUR N.V.

Patient Information leaflet

                                MAXITROL SUSPENSION EYE DROP
Dexamethasone / Neomycin Sulfate / Polymyxin B Sulfate (1mg / 3,500 IU
/ 6000 IU)
1
_CONSUMER MEDICATION INFORMATION LEAFLET (RIMUP)_
WHAT IS IN THIS LEAFLET
1.
What Maxitrol Suspension is used
for
2.
How Maxitrol Suspension works
3.
Before you use Maxitrol Suspension
4.
How to use Maxitrol Suspension
5.
While you are using it
6.
Side effects
7.
Storage and Disposal of Maxitrol
Suspension
8.
Product Description
9.
Manufacturer and Product
Registration Holder
10.
Date of revision
WHAT MAXITROL SUSPENSION_ _IS USED FOR
Maxitrol is indicated eye inflammation
and bacterial infections in the external
part of the eye.
HOW MAXITROL SUSPENSION_ _WORKS
Maxitrol combines two antibiotics,
neomycin sulfate and polymyxin B
sulfate, offering broad spectrum
antibacterial activity with the anti-
inflammatory activity of a corticosteroid,
dexamethasone, for combating certain
microbial infections.
BEFORE YOU USE MAXITROL SUSPENSION_ _
_When you must not use it _
Do not use Maxitrol Suspension
•
If you are allergic to dexamethasone,
neomycin, polymyxin B or any of
the other ingredients of Maxitrol
Suspension.
•
If you think you have:
o
Herpes simplex keratitis,
Smallpox, Chickenpox /
Herpes Zoster, or any other
viral infection of the eye
o
Fungal diseases of the eye
or an untreated parasitic
eye infection
o
Tuberculosis of the eye
_ _
Safety and effectiveness of MAXITROL
in children have not been established.
_ _
_Pregnancy and breast-feeding _
If you are pregnant or breast-feeding,
you think you may be pregnant or are
planning to have a baby, ask your doctor
or pharmacist for advice before using
this medicine. Maxitrol Suspension is not
recommended during pregnancy or
breast-feeding.
_ _
_ _
-
_Before you start to use it _
•
If you experience allergic reactions
with Maxitrol Suspension,
discontinue use and consult your
doctor. Allergic reactions may vary
from localized itching or skin redness
to severe allergic reactions
(anaphylactic reaction) or serious skin
reactions. These allergic reactions

                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1. NAME OF THE MEDICINAL PRODUCT
MAXITROL*	® sterile ophthalmic suspension
MAXITROL*	® sterile ophthalmic ointment
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
MAXITROL*	® ophthalmic suspension
1 ml of suspension contains 1 mg dexamethasone, 3,500 (International Units) IU of
neomycin sulfate and 6,000 IU polymyxin B sulfate.
Excipients with known effects: Benzalkonium Chloride 0.04 mg/ml.	Preservative: 1 ml of
suspension contains 0.04 mg benzalkonium chloride.
For the full list of excipients, see section 6.1.
MAXITROL*	® sterile ophthalmic ointment
1 g of ointment contains 1 mg dexamethasone, 3,500 IU neomycin sulfate and 6,000 IU
polymyxin B sulfate.
Preservative: 1 g of ointment contains 0.5 mg methylparaben and 0.1 mg propylparaben.
Excipients with known effects: methyl parahydroxybenzoate (E218), propyl
parahydroxybenzoate (E216), wool fat.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
MAXITROL*	® ophthalmic suspension
Sterile ophthalmic suspension
Opaque, white to pale yellow suspension, no agglomerates
MAXITROL*	® sterile ophthalmic ointment
Sterile ophthalmic ointment
A greasy, translucent to opaque and white to light yellow, homogeneous ointment, free of
lumps .
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Commented [LKL1]:	Editorial changes to align with	approved	information.
Commented [LKL2]:	Editorial changes to align with	CCDS. No change in approved information.
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Malay 13-07-2020